Septerna (NASDAQ:SEPN) Stock Price Down 6.3% – What’s Next?

Septerna, Inc. (NASDAQ:SEPN)’s stock price fell 6.3% on Monday . The company traded as low as $26.26 and last traded at $26.2250. 134,506 shares traded hands during mid-day trading, a decline of 29% from the average session volume of 189,530 shares. The stock had previously closed at $27.98.

Analyst Ratings Changes

SEPN has been the subject of several analyst reports. Wall Street Zen upgraded Septerna from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. HC Wainwright boosted their price objective on shares of Septerna from $26.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Jones Trading started coverage on shares of Septerna in a research note on Tuesday, December 23rd. They issued a “buy” rating and a $43.00 target price on the stock. Wells Fargo & Company upgraded shares of Septerna from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $18.00 to $28.00 in a report on Friday, November 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Septerna has a consensus rating of “Moderate Buy” and an average price target of $33.00.

Septerna Stock Performance

The company’s 50 day moving average is $24.98 and its 200 day moving average is $18.25. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -17.74 and a beta of 3.85.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. The company had revenue of $21.50 million for the quarter, compared to analyst estimates of $24.50 million. On average, equities research analysts anticipate that Septerna, Inc. will post -7.11 earnings per share for the current fiscal year.

Insider Buying and Selling at Septerna

In other news, SVP Daniel D. Long sold 3,501 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $18.06, for a total transaction of $63,228.06. Following the sale, the senior vice president directly owned 92,911 shares in the company, valued at approximately $1,677,972.66. The trade was a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 4.30% of the company’s stock.

Institutional Trading of Septerna

Large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. bought a new position in shares of Septerna during the third quarter valued at $36,000. Covestor Ltd lifted its holdings in Septerna by 55.8% during the 3rd quarter. Covestor Ltd now owns 3,620 shares of the company’s stock valued at $68,000 after purchasing an additional 1,296 shares during the last quarter. BNP Paribas Financial Markets boosted its position in Septerna by 88.0% in the third quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock valued at $78,000 after buying an additional 1,945 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Septerna by 15.0% during the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after buying an additional 1,315 shares during the last quarter. Finally, PharVision Advisers LLC acquired a new stake in shares of Septerna during the second quarter worth approximately $107,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.